PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People\'s Republic of China.\', \'Department of Intensive Medicine, Hongqi Hospital affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang, People\'s Republic of China.\', \'Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People\'s Republic of China.\', \'Department of Surgical Intensive Care Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People\'s Republic of China. Electronic address: carlg@163.net.\', \'Department of Intensive Medicine, Hongqi Hospital affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang, People\'s Republic of China. Electronic address: mdjxfj1971@126.com.\', \'Institute of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People\'s Republic of China; Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People\'s Republic of China. Electronic address: songjp@gzucm.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0924-8579(20)30427-110.1016/j.ijantimicag.2020.106216
?:hasPublicationType
?:journal
  • International journal of antimicrobial agents
is ?:pmid of
?:pmid
?:pmid
  • 33152450
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.699
?:rankingScore_hIndex
  • 107
is ?:relation_isRelatedTo_publication of
?:title
  • Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all